Repligen Corporation
$ 130.59
-2.06%
12 Jun - close price
- Market Cap 7,366,286,000 USD
- Current Price $ 130.59
- High / Low $ 135.72 / 130.43
- Stock P/E 143.51
- Book Value 37.33
- EPS 0.91
- Next Earning Report 2026-08-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.01 %
- ROE 0.03 %
- 52 Week High 175.77
- 52 Week Low 100.99
About
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$176.11
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-04 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.46 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RGEN
2026-06-11 23:22:00
RBC Capital has resumed coverage on Repligen Corp (RGEN) with an Outperform rating and a $160 price target, citing the company's diverse growth drivers and strengthening bioprocess market. Analysts anticipate Repligen's stock to rise over 40% based on these factors, predicting a return to mid-teens organic sales growth. The company reported strong Q1 2026 results with a 15% YoY revenue increase and beat analyst expectations for both revenue and adjusted EPS, reinforcing its full-year guidance.
2026-06-11 09:09:24
This article highlights Repligen Corp (NASDAQ: RGEN) as one of billionaire Lee Ainslie's top stock picks with significant upside potential. Analysts project a 41.26% upside, and RBC Capital has initiated coverage with an Outperform rating and a $160 price target, citing growth drivers, a strengthening bioprocess market, and strong Q1 2026 results. Repligen's focus is on accelerating profitable growth by making biological drug manufacturing more efficient.
2026-06-10 21:10:00
This article highlights Repligen Corp (NASDAQ:RGEN) as one of billionaire Lee Ainslie's top stock picks with significant upside potential. Analysts project the stock to rise over 40%, with RBC Capital resuming coverage with an Outperform rating and a $160 price target, citing growth drivers, a strengthening bioprocess market, and strong Q1 2026 results. Repligen, a bioprocessing company, focuses on accelerating profitable growth through its products that enhance the efficiency of biological drug manufacturing.
2026-06-08 20:09:41
Repligen (RGEN) has seen a 3.2% decline in its stock price since its last earnings report. The article questions whether the company can rebound from this recent downturn.
2026-06-05 23:10:01
Repligen Corp (RGEN) shares surged 4.0% to $126.55 on June 4, 2026. The stock is considered 27.7% undervalued according to GuruFocus' GF Value™ estimate of $174.94, despite its current P/E (TTM) of 140.6x being significantly above its 5-year median. The company holds a GF Score™ of 79/100, indicating strong growth and financial strength, though recent insider selling of $0.5 million suggests caution for investors.
2026-06-04 15:08:45
Repligen (RGEN) shares have dropped 3.2% since its last earnings report, underperforming the S&P 500. Despite this, the company's Q1 2026 adjusted earnings and revenues surpassed estimates, with strong year-over-year growth across its business franchises. While Repligen lowered its full-year 2026 revenue guidance, it raised its EPS outlook, leading to varied analyst sentiment and a Zacks Rank #3 (Hold).
